Bharat Biotech submits phase 3 trial data of COVAXIN vaccine to WHO for approval

On Wednesday, India’s indigenous COVID vaccine ‘Covaxin’ manufacturer Bharat Biotech has submitted its phase-3 clinical trial results to the World Health Organization (WHO) for clearance. Hyderabad-based Bharat Biotech’s pre-submission meeting has been scheduled on June 23 for evaluation of the WHO’s Emergency Use Listing (EUL) of its indigenous COVID-19 vaccine Covaxin.

Credits – Source – https://ift.tt/3gxvtrZ

The post Bharat Biotech submits phase 3 trial data of COVAXIN vaccine to WHO for approval appeared first on Stay in Gurgaon.

Comments

Popular posts from this blog

Flat sale of flu drugs hints at no unusual rise in infections

Sauteed potatoes with kale recipe

Divya Dutta: I was an ardent Bachchan fan